Progranulin concentration in relation to bone mineral density among obese individuals

ABSTRACT

Objective

Adipose tissue, particularly visceral adipose tissue, secretes a variety of cytokines, among which progranulin is a glycoprotein related to the immune system. Along with other secreted proteins, progranulin may be associated with bone mineral density. The aim of this study was to find out whether there are associations between the progranulin and bone mineral density among obese people.

Subjects and methods

This cross-sectional study was conducted on 244 obese participants (aged 22-52). Serum progranulin, high sensitive C-reactive protein, oxidised-low dencity lipoprotein, tumor necrosis factor-α, parathormone, vitamin D, and interleukins of 1 β, 4, 6, 10, 13, and 17 concentrations were measured. Anthropometric measurements, body composition and bone mineral density were also assessed.

Results

Serum progranulin was directly associated with interleukin-6 and interleukin-1β, while it had a negative association with interleukin-17 and tumor necrosis factor-α. We also observed a statistically significant direct association between progranulin concentration and visceral fat, abdominal fat, waist, abdominal and hip circumferences, hip T-score, and Z-score and T-score for the lumbar region. A partial correlation test has also shown a significant positive correlation regarding serum progranulin and the hip Z-score. Moreover, progranulin level is inversely associated with ospteopenia (P = 0.04 and CI: 0.17,0.96).

Conclusion

Our study revealed that central obesity may be related to increased progranulin concentration. In addition, progranulin concentration was directly related to bone formation parameters, which indicates the protective effects of progranulin on bone density. Further studies are needed to clarify the exact mechanisms underlying these associations.

Keywords
Bone mineral density; progranulin; obesity; osteopenia; cytokine

INTRODUCTION

Compelling evidence indicates that obesity is associated with inflammation and immune system function (¹,²). Due to the function of adipose tissue as an endocrine gland which secretes several cytokines, this association has frequently been attributed to central obesity (³). Indeed, some studies have regarded inflammation as a risk factor for osteoporosis (⁴,⁵). However, the precise mechanism underlying the role of inflammation as well as the association between obesity, inflammation and osteoporosis has not yet been clarified. Some data suggest that cytokines secreted from adipose tissue may play a major role in osteoporosis (⁶). Osteoporosis is considered as one of the most serious chronic diseases in the present century (⁷). According to the international definition, osteoporosis defined as a 2.5 Standard Deviation (SD) reduction in Bone Mineral Density (BMD) (⁸,⁹).

Progranulin (PGRN) is a cytokine that is secreted from adipose tissue, and also, is a secretory 593-amino acid glycoprotein with a widespread expression in different cells, such as immune system cells (¹⁰). PGRN is also regarded as a growth factor, similar to IGF-1, with inflammatory properties (¹¹). There are some studies that suggested PGRN concentration is associated with the extent of visceral adiposity (¹²,¹³). It seems that PGRN can activate some inflammatory pathways (¹⁴) and, as mentioned, this can affect BMD (¹⁵) and facilitate the development of osteoporosis. Furthermore, a recent study by Romanello and cols. has suggested a proliferative and pro-survival effect of PGRN on osteocyte-like cells. The research demonstrated that PGRN can induce phosphorylation of mitogenactivated protein kinase in both HOBIT and osteocytic cells. Moreover, the authors reported that Risedronate, a bisphosphonate drug which has been widely used in the treatment of osteoporosis, induces the expression as well as the secretion of PRGN in the HOBIT secretome. These findings suggested the possible role of PGRN in osteoblast/osteocyte biology (¹⁶).

The aim of this study was to find out whether there are associations between progranulin and bone mineral density among obese people.

MATERIALS AND METHODS

Study population

In this cross sectional study, 244 class I and II obese (30 ≤ BMI < 40 kg/m²) participants (22 to 52 years old) were recruited from Shariati hospital. The study protocol was approved by the ethics committee of the Endocrinology and Metabolism Research Center of Tehran University of Medical Sciences (TUMS) with the following identification: 90-03-27-14619. The inclusion criteria namely were having a BMI in the range of 30-39.99kg/m², and being aged from 22-52. Exclusion criteria were defined as having any history of inflammatory conditions or inflammatory diseases, cardiovascular disease, diabetes mellitus, thyroid diseases, cancer or malignancies, hypertension or hypotensive drug abuse, hepatic, heart, or renal disease, chronic or acute infections, smoking, drug or alcohol abuse, and pregnancy. Each participant was completely informed regarding the study protocol and provided a written and informed consent form before taking part in the study.

Laboratory measurements

All blood samples were collected from 8:00 to 10:00 a.m. after an 8-12 hours fast at the EMRC laboratory in Shariati hospital of TUMS. To collect serums, blood samples were centrifuged for 10 minutes at 3000 rpm. Serum samples were aliquoted and stored at -80°C until they were analyzed. Serum high sensitive C-reactive protein (hsCRP), as a sensitive marker of inflammation, was measured by an imonoturbidimetric assay (Randox laboratories kit, Hitachi 902). Serum concentrations of adipokines (including interleukins of 1 β, 4, 6, 10, 13, and 17) were measured in triplicate and 10 replicates per EIA plate under internal quality controls. Serum concentration of interleukin 6 (IL-6) was analyzed by EIA kit (Enzo Life Sciences, Inc. Sensitivity: 3.75 pg/mL; inter-assay variability: 3.7%; intra-assay variability: 3.9%). Serum concentration of interlukin 4 (IL-4) was also assessed by EIA kit (Enzo Life Sciences, Inc. Sensitivity: < 2 pg/mL; in intra CV was 4.3% and interCV was 4.7%). TNF-α concentration was determined by EIA kit (Enzo Life Sciences, Inc. Sensitivity: 8.43 pg/mL; inter-assay variability: 6%; intra-assay variability: 3.6%). Serum PGRN concentration was measured by ELISA kit (AdipoGen; Seoul, South Korea. Sensitivity: 32 pg/mL; inter-assay variability: 4.7%; intra-assay variability: 3.79%) under internal quality controls (¹⁷).

Anthropometric measurement

Weights and heights were measured with participants wearing light clothes and without shoes. Weight was measured using a digital scale (Sega 707, Hamburg, Germany) to the nearest 0.1 kg. Height was measured using a stadiometer (Seca, Hamburg, Germany) to the nearest 0.1 cm. Body mass index (BMI) was calculated using the “weight(kg)/height²(m²)” equation. Waist circumference (WC) was measured in the middle point of the iliac crest and ribcage.

Body composition analysis

Participant body composition was assessed by Body Composition Analyzer BC-418MA – Tanita (United Kingdom). This Bioelectrical Impedance Analyzer (BIA) sends out a very weak electric current across the body to measure its electrical resistance. Before assessing body composition, the manufacturer's instructions were followed to ensure accurate assessment. Participants were asked not to exercise vigorously, put aside any electrical device (mobile phone, etc.), or to intake excessive fluid or food. As changes in bodywater distribution and body temperature can have a major impact on measurements, they were performed in the morning in a fasting condition (always urinating before taking measurements, etc.) to get a more accurate measurement every single time. To prevent inaccurately low body fat percentage measurements and other measurement errors, both arms were always held straight down when taking measurements. The device calculates the body fat percentage, fat mass and fat-free mass, and predicts the muscle mass on the basis of data obtained by dual-energy X-ray absorptiometry using bioelectrical impedance analysis (¹⁸).

BMD measurement

In this study, BMD was measured by the Dual Energy X-ray Absorptiometery (DEXA) method at the hip and lumbar spine (vertebra L2-L4). The average coefficient of variation (CV) for measuring BMD in our device was 1.04%. According to the World Health Organization (WHO) standard, normal bone mass was defined as BMD ≥ -1 standard deviation (SD), osteopenia as -1 < BMD <-2.5 SD, and osteoporosis as BMD ≤ -2.5 SD. Osteoporosis was diagnosised based on the T-score (¹⁹).

Statistical analysis

The study population was divided into two groups based on median PGRN concentration (< 113.30 and ≥ 113.30 pg/mL), then the study variables were compared among the two groups using an independent T-test. The association between serum PGRN concentration and BMD measurements was examined through a partial correlation test after adjusting for weight and fat mass. The level of statistical significance was set to < 0.05 All statistical analysis was performed using SPSS version 16.0 (Chicago, IL).

RESULTS

The particpants’ mean (±SD) of age, height, BMI, and weight were 39.12 ± 11.90 years, 162.42 ± 8.80 cm, 35.32 ± 3.98 kg/m², and 93.68 ± 14.75 kg, respectively. The mentioned variables were 37.10 ± 12.77 years, 176.44 ± 6.89 cm, 35.30 ± 3.49 kg/m², and 108.42 ± 15.74 kg respectively, in men, and 39.60 ± 11.68 years, 159.87 ± 6.38 cm, 35.33 ± 4.10 kg/m², and 90.15 ± 12.14 kg, respectively in women. From 244 participants, 68 subjects (27.86%) were osteopenic and 176 individuals (72.14%) had normal BMD. The population characteristics, body composition, BMD, and laboratory measurements of participants are summarized in Table 1. As shown in the table, mean serum parathyroid hormone (PTH) and vitamin D (VitD) concentrations of participants were above and within the normal ranges respectively (10-55 pg/mLfor PTH and 30-74 ng/mL for VitD). The visceral fat rating showed that central obesity may be more serious in men compared to women (Table 1). Additionally, the DEXA assay showed an osteopenic condition only in the lumbar spine (L2-L4) of women, when BMD was expressed as mean ± (SD) T-score (T-score < -1).

Table 1
Population characteristics, body composition, bone mineral density and laboratory measurements of the participants

Variables	Men (n = 57)	Women (n = 187)
Anthropometry:
Age (years)	37.10 ± 12.77	39.60 ± 11.68
Weight (kg)	108.42 ± 15.74	90.15 ± 12.14
Height (21)	176.44 ± 6.89	159.87 ± 6.38
BMI (kg/cm2)	35.30 ± 3.49	35.33 ± 4.10
Fat percent (%)	30.11 ± 4.23	42.43 ± 4.75
Fat mass (kg)	32.98 ± 8.22	38.48 ± 8.21
Fat-free mass (kg)	75.41 ± 9.53	51.66 ± 6.57
Visceral fat rating (kg)	14.24 ± 4.05	9.99 ± 2.46
Trunk fat percent (%)	20.80 ± 4.67	18.75 ± 4.37
Biochemistry characteristics:
Progranulin (pg/mL)	119.22 ± 30.13	120.86 ± 44.02
Vitamin D (ng/mL)	32.43 ± 4.50	38.28 ± 36.39
Hs-CRP (mg/L)	2.35 ± 2.32	4.75 ± 5.86
Ox-LDL (U/dL)	556.31 ± 58.85	583.02 ± 85.54
TNF-α (pg/mL)	13.68 ± 30.92	7.67 ± 14.01
PTH (pg/mL)	84.74 ± 54.19	89.89 ± 49.90
IL-1β (pg/mL)	0.01 ± 0.00	0.01 ± 0.00
IL-4 (pg/mL)	1.47 ± 0.86	1.81 ± 1.07
IL-6 (pg/mL)	30.28 ± 18.99	24.09 ± 20.66
IL-10 (pg/mL)	31.85 ± 38.65	14.12 ± 15.44
IL-13 (pg/mL)	32.35 ± 33.60	41.61 ± 30.41
IL-17 (pg/mL)	0.28 ± 0.13	0.95 ± 1.33
Bone densitometry:
Hip BMD	1.17 ± 0.16	1.08 ± 0.16
Hip T-score	0.64 ± 1.27	0.58 ± 1.10
Hip Z-score	0.18 ± 1.03	0.22 ± 0.99
Lumbar BMD	1.24 ± 0.18	1.19 ± 0.16
Lumbar T-score	0.24 ± 1.58	-0.10 ± 1.17
Lumbar Z-score	-0.48 ± 1.45	-0.68 ± 1.13

• BMI: body mass index; Hs-CRP: high sensitive C-reactive protein; TNF-α: tumor necrosis factor-α; IL: interleukin; Ox-LDL: oxidized-low density lipoprotein; PTH: parathormone; BMD: bone mineral density.

Association between PGRN, anthropometric measures, and body composition

Our analysis revealed that mean BMI, fat percentage, fat mass, fat free mass, visceral fat, trunk fat, waist circumference, abdominal and hip circumferences were greater in the high serum PGRN concentration group compared to the low serum PGRN concentration one (Table 2). However, the association was statistically significant for visceral fat, trunk fat, waist, abdominal and hip circumferences (p < 0.05). We also found a higher mean of age (p = 0.17) and total body water (p = 0.28) in the high serum PGRN concentration group, which were not significant. In addition, a difference in the Central Adiposity Index (CAI) lower than 25 and above 75 centile value was seen in participants, with the following results reported: waist circumference was 95.83 cm ± 3.64 SE and 98.16 ± 1.97 in participants in the lower than 25 and above 75 centile for progranulin value, respectively, which was not significant (P-value = 0.12). Results also highlighted values of WHR (0.86 ± 0.01 and 0.87 ± 0.01 and P-value = 0.75), visceral fat (6.30 ± 0.66 and 7.88 ± 0.41 and P-value < 0.0001) and BMI (27.85 ± 1.12 and 31.06 ± 0.65 and P-value = 0.001) in lower than 25 and above 75 centile for progranulin value, respectively.

Table 2
Anthropometric measures and body composition between groups with low and high concentrations of PGRN

Variables	Relative PGRN concentration (n = 244)		P value
	Low concentration (n = 122)	High concentration (n = 122)
Age (years)	38.08 ± 12.86	40.16 ± 11.22	0.17
BMI (kg/cm2)	34.54 ± 3.85	35.12 ± 4.44	0.27
Fat percent (%)	40.79 ± 6.56	40.86 ± 6.32	0.93
Fat mass (kg)	36.32 ± 8.86	37.40 ± 9.00	0.34
Fat-free mass (kg)	52.50 ± 9.53	53.76 ± 8.98	0.28
Visceral fat rating (kg)	9.56 ± 2.94	10.45 ± 2.71	0.01
Trunk fat percent (%)	17.57 ± 5.42	19.13 ± 4.39	0.01
Waist circumference (21)	97.00 ± 9.99	101.56 ± 9.46	< 0. 001
Abdominal circumference (21)	111.42 ± 8.88	116.45 ± 10.56	< 0. 001
Hip circumference (21)	114.00 ± 7.09	118.38 ± 11.55	< 0.001
TBW (%)	38.42 ± 6.99	39.36 ± 6.57	0.28

• BMI: body mass index; TBW: total body water.

Association between PGRN and other cytokines

According to an independent T-test, mean serum concentrations of IL-1β, IL-13, Il-10, Il-6, and Il-4 were greater in those in the high serum PGRN concentration group (Table 3), while mean serum levels of IL-17, TNF-α, and hs-CRP were lower in the high PGRN concentration group compared to the low serum PGRN concentration one. However, it should be noted that these associations were statistically significant only for IL-1β, IL-17, IL-6, and TNF-α (p < 0.05).

Table 3
Cytokine concentrations between groups with low and high concentrations of PGRN

Variables	Relative PGRN concentration (n = 244)		P value
	Low concentration (n = 122)	High concentration (n = 122)
Hs-CRP (mg/L)	4.91 ± 4.98	4.73 ± 6.99	0.81
TNF-α (pg/mL)	10.67 ± 19.68	3.53 ± 2.09	< 0.001
IL-1β (pg/mL)	0.01 ± 0.00	0.02 ± 0.01	< 0.001
IL-4 (pg/mL)	2.02 ± 1.35	2.21 ± 0.79	0.18
IL-6 (pg/mL)	16.68 ± 11.80	28.29 ± 28.15	< 0.001
IL-10 (pg/mL)	12.43 ± 12.21	15.51 ± 22.45	0.18
IL-13 (pg/mL)	41.83 ± 29.24	47.01 ± 31.44	0.18
IL-17 (pg/mL)	1.31 ± 1.55	0.45 ± 0.61	< 0.001

• Hs-CRP: high sensitive C-reactive protein; TNF-α: tumor necrosis factor-α; IL: interleukin.

Association between PGRN and bone health variables

According to an independent T-test, mean hip BMD and hip T-score and Z-score, as well as T-score and Z-score for the lumbar spine (L2-L4 vertebra) were greater in the high serum PGRN concentration group (Table 4). However, it should be noted that these associations were statistically significant only for hip T-score and Z-score and the lumbar T-score (p < 0.05) and was marginally significant considering total BMD (p = 0.05). Moreover, a partial correlation between serum PGRN concentration and BMD measurements adjusted for fat mass, indicated a significant positive correlation with hip Z-score (r = 0.35, p < 0.05). However, after factoring in weight, none of the observed correlations were significant (Table 5, part A). Additionally, a binary regression analysis was done to strengthen our findings, (as shown in Table 5, part B). After adjustment for age and BMI, the PGRN level was strongly and inversely associated with osteopenia (P = 0.04 and CI: 0.17,0.96). Figure 1 demonstrates that there was a significantly lower number of osteopenic patients in the high serum PGRN concentration group.

Table 4
Bone mineral density measurements between groups with low and high concentrations of PGRN

Variables	Relative PGRN concentration (n = 244)		P value
	Low concentration (n = 122)	High concentration (n = 122)
Vitamin D (ng/mL)	32.76 ± 35.92	28.69 ± 13.99	0.24
PTH (pg/mL)	92.00 ± 56.76	105.74 ± 63.04	0.09
Hip BMD	1.07 ± 0.23	1.12 ± 0.17	0.05
Hip T-score	0.18 ± 0.79	1.05 ± 1.50	< 0.001
Hip Z-score	-0.13 ± 0.89	0.68 ± 1.30	< 0.001
Lumbar BMD	1.15 ± 0.13	1.18 ± 0.16	0.10
Lumbar T-score	-0.41 ± 1.16	-0.08 ± 1.36	0.04
Lumbar Z-score	-0.85 ± 1.07	-0.61 ± 1.38	0.13

• BMD: bone mineral density; PTH: parathormone.

Table 5
A: Partial correlation between PGRN concentration and bone mineral density measurements

	Adjusted for	Hip BMD	Hip T-score	Hip Z-score	Lumbar BMD	Lumbar T-score	Lumbar Z-score
Progranulin concentration (pg/mL)	r
	Weight	0.21	0.32	0.33	0.24	0.24	0.26
	P value	0.25	0.75	0.65	0.19	0.18	0.15
	r
	Fat mass	0.19	0.33	0.35	0.22	0.23	0.26
	P value	0.30	0.06	0.04	0.22	0.21	0.14

• BMD: bone mineral density.

B:
Binary regression model for analyzing the relationship between Progranulin Concentration and risk of osteopenia in obese people

PGRN	Crude model			Model 1			Model 2			Model 3
	B ± SE	CI	P	B ± SE	CI	P	B ± SE	CI	P	B ± SE	CI	P
	-0.47 ± 0.32	0.33, 1.69	0.14	-0.52 ± 0.33	0.30, 1.30	0.11	-0.90 ± 0.99	0.17, 0.96	0.04	-0.81 ± 0.44	0.81, 1.07	0.07

• Model 1: Adjusted for age; Model 2: Adjusted for age and BMI; Model 3: Adjusted for age, BMI and gender; PGRN: Progranulin

Figure 1
Variety of osteopenia by categorized progranulin level.

Additionally, we found that serum PTH was greater in the high serum PGRN concentration group (p = 0.09), while vitamin D was lower in this group, in comparision with those who had lower serum concentrations of PGRN (p = 0.24). However, none of them were statistically significant.

Meanwhile, comparing the prevalence of osteopenia among these two groups indicated that the osteopenic patients had considerably lower serum PRGN concentrations (Figure 1).

DISCUSSION

In the current study, a significant association was found between PGRN concentration and the serum levels of some cytokines, which can be explained by the regulatory roles of PGRN on signaling pathways. To illustrate this, it can be observed that serum PGRN was directly associated with the levels of serum IL-1β and Il-6, while it was inversely related to IL-17 and TNF-α serum levels. Results also showed significant associations between PGRN concentration and visceral and trunk fat. Increased hip, waist and abdominal circumferences were also observed in the higher concentration PGRN group. Furthermore, high PGRN was related to higher hip T- and Z-score and also lumbar T-score.

These findings agreed with Zhang and cols.'s study, which found a significant linear correlation between PGRN concentration and IL-6 serum levels in patients with primary Sjögren's syndrome (²⁰). Frampton and cols. also have reported that Il-6 can activate the ERK1/2/RSK1/C/EBPβ pathway and PGRN synthesis as a consequence (²¹). Furthermore, several studies have shown that PGRN may antagonize TNF-α by the activation of its receptors, therefore PGRN may have some anti-inflammatory properties (²²). Studies have also regarded TNF-α as an inhibitor of osteoblast differentiation, as well as an activator of osteoclastogenesis (²³).

According to previous studies, IL-6 and IL-1β induce bone resorption and inhibit bone formation (²⁴). Although it has been widely reported that IL-17 mediates diverse inflammatory processes, its effects on bone resorption has recently been documented (²⁵). It seems that IL-17 and TNF-α synergically stimulate bone resorption (²⁶).

This study demonstrated a significant linear association between PGRN concentration and central obesity parameters including visceral fat, abdominal fat, waist, abdominal and hip circumferences. Along the same lines as these findings, previous studies have found that the PGRN gene expresses in macrophages existing in fat tissues, especially visceral fat (¹²,¹³). Youn and cols. reported that PGRN concentration was significantly associated with central and general obesity parameters, which can be described by stimulating omental adipose tissue macrophage infiltration by PGRN (¹³). Pradeep and cols. measured PGRN concentrations in serum and gingival crevicular fluid of 40 patients suffering from chronic periodentitis with and without obesity. The authors reported that the serum PGRN concentration was higher in both serum and gingival crevicular fluid in obese periodentitic patients; which can indicate that inflammation related to periodentitis and obesity may also be associated with PGRN concentration (²⁷). In agreement with these findings, Hossein-Nezhad and cols. demonstrated an association between BMI and central obesity with PGRN gene expression and circulation levels, which revealed that PGRN is related to obesity through glucose homeostasis and metabolism regulation (²⁸).

Since we observed a linear association between PGRN concentration and central obesity parameters, changes in the secretion of cytokines may be attributed to adipose tissue expansion. Similarly, Zizza and cols.'s study found a negative association between IL-17 and visceral obesity (²⁹). Furthermore, Mohamed-Ali's study showed that subcutaneous fat was associated with IL-6 but not with TNF-α (³⁰).

Results from previous studies have indicated that visceral fat, as well as subcutaneous fat, as measured by computer tomography scan, and BMI have a negative association with bone density. More importantly, correlations regarding visceral fat and decreased bone density remained statistically significant even after adjustment for age, sex, and BMI (³¹). This study's findings demonstrate PGRN's effect on osteogenesis, as can be seen in the hip T-score and Z-score and T-score for the lumbar vertebra, which were significantly associated with PGRN concentration. Similarly to this study, Romanello and cols. demonstrated the proliferative and pro-survival effects of PRGN on osteocyte-like cells (¹⁶). Likewise, a recent study by Oh and cols. indicated a new regulatory axis by which PGRN may induce osteoclastogenesis. This axis is regarded as the (RANKL)/RANK axis, and PGRN may induce this pathway by stimulating PIRO expression (³²). Documented results showed that recombinant human PGRN can induce phosphorylation of mitogenactivated protein kinase in both HOBIT and osteocytic cells and induce cell proliferation and survival. Moreover, they found that Risedronate, a widely used bisphosphonate drug in the treatment of osteoporosis, can induce the expression and secretion of PGRN in the HOBIT secretome (¹⁶). These findings have shown the probable preventive effects of PGRN on osteoporosis by modulating bone loss. In addition, results from previous studies reported that PGRN growth factor enhances chondrocyte differentiation and endochondral ossification by regulating BMP-2 and TNF signaling, therefore PGRN injections may play an important role in bone healing, particularly in fracture conditions (³³). A disadvantage of the present cross-sectional study is that it does not allow definite conclusions to be made regarding cause and effect. PGRN might affect BMD or vice versa.

In conclusion, the findings of this study showed that central obesity expansion is associated with increased PGRN concentration. PGRN has some paradoxical relation with the levels of cytokine secretion, in that it has a direct association with the secretion of IL-1β and IL-6, while it inhibits the secretion of IL-17 and TNF-α. According to the aforementioned mechanisms, these changes in cytokine secretion have both degenerative and protective effects on bone structure and BMD. Aditionally, the association between obesity and bone mineral density has been demonstrated by several studies, though its effects depend on the definition of obesity; if obesity is regarded as increased body fat levels, it can be considered as a risk factor for a lower BMD, which can be affected by increased adipokines, subsequently causing a lower BMD (³⁴). However, obesity seems to play its role as a protective factor against osteoporosis if it is defined as an increase in body weight, which can be explained by a higher level of circulating estradiol, increased peak bone mass and greater gravitational load (³⁵). The direct observed association between PGRN concentration and bone formation parameters indicates that PGRN may have some bone-protective effects through various mechanisms other than cytokine secretion regulation. Further studies are needed to address the cellular and molecular mechanisms of both general and central obesity, as well as PGRN's effects on bone formation and absorption.

Acknowledgment

we are particularly grateful to all participants in the study for their dedication and contribution to the research. This study was supported by Tehran University of Medical Sciences Grant for research (ID: 14619, 31818).

REFERENCES

• ¹
  Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4-12.
• ²
  de Heredia FP, Gómez-Martínez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc. 2012;71(2):332-8.
• ³
  Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation: The ATTICA study. Atherosclerosis. 2005 Dec;183(2):308-15.
• ⁴
  Al-Daghri NM, Yakout S, Al-Shehri E, Al-Fawaz HA, Aljohani N, Al-Saleh Y. Inflammatory and bone turnover markers in relation to PTH and vitamin D status among saudi postmenopausal women with and without osteoporosis. Int J Clin Exp Med. 2014;7(10):3528-35.
• ⁵
  Zhang J, Fu Q, Ren Z, Wang Y, Wang C, Shen T, et al. Changes of serum cytokines-related Th1/Th2/Th17 concentration in patients with postmenopausal osteoporosis. Gynecol Endocrinol. 2015;31(3):183-90.
• ⁶
  Gonnelli S, Caffarelli C, Nuti R. Obesity and fracture risk. Clin Cases Miner Bone Metab. 2014;11(1):9-14.
• ⁷
  Kehler T. Epidemiology of osteoporosis and osteoporotic fractures. Reumatizam. 2014;61(2):60-4.
• ⁸
  World Health Organization. Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Technical Report Series 843. Geneva: WHO, 1994.
• ⁹
  Mahan L, Escott-Stump S, Raymond JL, Krause MV. Krause's Food & the Nutrition Care Process, (Krause's Food & Nutrition Therapy). Philadelphia: WB Saunders. Elsevier; 2012.
• ¹⁰
  Luo L, Lü L, Lu Y, Zhang L, Li B, Guo K, et al. Effects of hypoxia on progranulin expression in HT22 mouse hippocampal cells. Mol Med Rep. 2014;9(5):1675-80.
• ¹¹
  Wei Z, Huang Y, Xie N, Ma Q. Elevated expression of secreted autocrine growth factor progranulin increases cervical cancer growth. Cell Biochem Biophys. 2015;71(1):189-93.
• ¹²
  Tanaka Y, Takahashi T, Tamori Y. Circulating progranulin level is associated with visceral fat and elevated liver enzymes: significance of serum progranulin as a useful marker for liver dysfunction. Endocr J. 2014;61(12):1191-6.
• ¹³
  Youn BS, Bang SI, Klöting N, Park JW, Lee N, Oh JE, et al. Serum progranulin concentrations may be associated with macrophage infiltration into omental adipose tissue. Diabetes. 2009;58(3):627-36.
• ¹⁴
  Ong CHP, Zhiheng H, Kriazhev L, Shan X, Palfree RGE, Bateman A. Regulation of progranulin expression in myeloid cells. Am J Physiol Regul Integr Comp Physiol. 2006;291(6):R1602-R12.
• ¹⁵
  Katsuyama E, Miyamoto H, Kobayashi T, Sato Y, Hao W, Kanagawa H, et al. Interleukin-1 receptor-associated kinase-4 (IRAK4) promotes inflammatory osteolysis by activating osteoclasts and inhibiting formation of foreign body giant cells. J Biol Chem. 2015;290(2):716-26.
• ¹⁶
  Romanello M, Piatkowska E, Antoniali G, Cesaratto L, Vascotto C, Iozzo RV, et al. Osteoblastic cell secretome: a novel role for progranulin during risedronate treatment. Bone. 2014;58:81-91.
• ¹⁷
  Hossein-Nezhad A, Mirzaei K, Ansar H, Khooshechin G, Ahmadivand Z, Keshavarz SA. Mutual role of PGRN/TNF-α on osteopenia developing in obesity's inflammation state. Minerva Med. 2012;103(3):165-75.
• ¹⁸
  Mirzaei K, Hossein-Nezhad A, Emamgholipour S, Ansar H, Khosrofar M, Tootee A, et al. An exonic peroxisome proliferator-activated receptor-γ coactivator-1α variation may mediate the resting energy expenditure through a potential regulatory role on important gene expression in this pathway. J Nutrigenet Nutrigenomics. 2012;5(2):59-71.
• ¹⁹
  Hossein-Nezhad A, Khoshniat Nikoo M, Mirzaei K, Mokhtarei F, Aghaei Meybodi HR. Comparison of the bone turn-over markers in patients with multiple sclerosis and healthy control subjects. Eur J Inflamm. 2010;8(2):67-73.
• ²⁰
  Zhang N, Yang N, Chen Q, Qiu F, Li X. Upregulated expression level of the growth factor, progranulin, is associated with the development of primary Sjögren's syndrome. Experimental and therapeutic medicine. 2014;8(5):1643-7.
• ²¹
  Frampton G, Invernizzi P, Bernuzzi F, Pae HY, Quinn M, Horvat D, et al. Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut. 2012;61(2):268-77.
• ²²
  Tian Q, Zhao S, Liu C. A solid-phase assay for studying direct binding of progranulin to TNFR and progranulin antagonism of TNF/TNFR interactions. Methods Mol Biol. 2014;1155:163-72.
• ²³
  Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106(12):1481-8.
• ²⁴
  Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol. 1990;145(10):3297-303.
• ²⁵
  Boron% D, Agnieszka SM, Daniel K, Anna B, Adam K. Polymorphism of interleukin-17 and its relation to mineral density of bones in perimenopausal women. Eur J Med Res. 2014;19:69.
• ²⁶
  Shen F, Ruddy MJ, Plamondon P, Gaffen SL. Cytokines link osteoblasts and inflammation: microarray analysis of interleukin-17- and TNF-alpha-induced genes in bone cells. J Leukoc Biol. 2005;77(3):388-99.
• ²⁷
  Pradeep AR, Priyanka N, Prasad MV, Kalra N, Kumari M. Association of progranulin and high sensitivity CRP concentrations in gingival crevicular fluid and serum in chronic periodontitis subjects with and without obesity. Dis Markers. 2012;33(4):207-13.
• ²⁸
  Hossein-Nezhad A, Mirzaei K, Ansar H, Emam-Gholipour S, Tootee A, Keshavarz SA, et al. Obesity, inflammation and resting energy expenditure: possible mechanism of progranulin in this pathway. Minerva Endocrinol. 2012;37(3):255-66.
• ²⁹
  Zizza A, Guido M, Grima P. Interleukin-17 regulates visceral obesity in HIV-1-infected patients. HIV Med. 2012;13(9):574-7.
• ³⁰
  Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82(12):4196-200.
• ³¹
  Zhang P, Peterson M, Su GL, Wang SC. Visceral adiposity is negatively associated with bone density and muscle attenuation. Am J Clin Nutr. 2015;101(2):337-43.
• ³²
  Oh J, Kim JY, Kim HS, Oh JC, Cheon YH, Park J, et al. Progranulin and a five transmembrane domain-containing receptor-like gene are the key components in receptor activator of nuclear factor κB (RANK)-dependent formation of multinucleated osteoclasts. J Biol Chem. 2015;290(4):2042-52.
• ³³
  Zhao YP, Tian QY, Frenkel S, Liu CJ. The promotion of bone healing by progranulin, a downstream molecule of BMP-2, through interacting with TNF/TNFR signaling. Biomaterials. 2013;34(27):6412-21.
• ³⁴
  Aguirre L, Napoli N, Waters D, Qualls C, Villareal DT, Armamento-Villareal R. Increasing adiposity is associated with higher adipokine levels and lower bone mineral density in obese older adults. J Clin Endocrinol Metab. 2014;99(9):3290-7.
• ³⁵
  Shetty S, Kapoor N, Naik D, Asha HS, Prabu S, Thomas N. Osteoporosis in healthy South Indian males and the influence of life style factors and vitamin D status on bone mineral density. J Osteoporosis. 2014;2014: ID 723238.

Publication Dates

• Publication in this collection
  05 Apr 2018
• Date of issue
  Mar-Apr 2018

History

• Received
  03 Nov 2016
• Accepted
  01 Mar 2017